RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
27.54
-0.59 (-2.11%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close28.14
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,045,201
Market Cap189.962B
Beta0.53
PE Ratio (TTM)21.04
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.08 (3.87%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • The story of how Bill Gates's dad saved Starbucks
    Yahoo Finance Video12 days ago

    The story of how Bill Gates's dad saved Starbucks

    And who knew that Bill Gates dad saved the company in the 1980s?

  • Roche’s Hemlibra Could Drive Long-Term Growth
    Market Realist14 hours ago

    Roche’s Hemlibra Could Drive Long-Term Growth

    In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs, which included revenues of 18 million Swiss francs from the US market and 5 million Swiss francs from the European market.

  • Tecentriq Could Be Roche’s Long-Term Growth Driver
    Market Realist16 hours ago

    Tecentriq Could Be Roche’s Long-Term Growth Driver

    Roche’s (RHHBY) Tecentriq (atezolizumab), a PD-L1 blocker is approved for use in the treatment of individuals with metastatic urothelial carcinoma in patients. These patients would not be eligible candidates for cisplatin-containing chemotherapy, or showed disease progression after treatment with platinum-containing chemotherapy.

  • How Tecentriq Is Positioned after Q1 2018
    Market Realist17 hours ago

    How Tecentriq Is Positioned after Q1 2018

    In the first quarter, Roche’s (RHHBY) Tecentriq generated revenues of 139 million Swiss francs compared to 113 million Swiss francs in the first quarter of 2017, which reflected ~29% year-over-year (or YoY) CER (constant exchange rate) growth. In the US market, Tecentriq witnessed ~5% YoY growth in the first quarter.

  • Roche’s Ocrevus Witnessed Solid Growth in Q1 2018
    Market Realist2 days ago

    Roche’s Ocrevus Witnessed Solid Growth in Q1 2018

    In the first quarter, Roche’s (RHHBY) Ocrevus generated revenues of 479 million Swiss francs compared to 369 million Swiss francs in the fourth quarter of 2017, which reflected ~30% sequential growth.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist2 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?
    Simply Wall St.2 days ago

    Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?

    Roche Holding AG (SWX:ROG) is currently trading at a trailing P/E of 22.2x, which is lower than the industry average of 24.8x. While ROG might seem like an attractive stockRead More...

  • Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business
    Investor's Business Daily2 days ago

    Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business

    Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.

  • Roche (RHHBY) Announces Positive Data on Hemophilia Drug
    Zacks2 days ago

    Roche (RHHBY) Announces Positive Data on Hemophilia Drug

    Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.

  • How Roche’s Herceptin and Kadcyla Performed in Q1 2018
    Market Realist3 days ago

    How Roche’s Herceptin and Kadcyla Performed in Q1 2018

    Roche’s (RHHBY) Herceptin reported revenues of 1.77 billion Swiss francs in the first quarter compared to 1.76 billion Swiss francs in the first quarter of 2017, which reflected ~2.0% YoY (year-over-year) growth at constant exchange rates. In the fourth quarter of 2017, Herceptin reported revenues of 1.78 billion Swiss francs, which reflects a flat revenue trend compared to the first quarter.

  • The Performance of Roche’s Diagnostics Division in Q1 2018
    Market Realist3 days ago

    The Performance of Roche’s Diagnostics Division in Q1 2018

    Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist3 days ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Reuters3 days ago

    Roche drug dramatically reduces bleeds in key haemophilia tests

    Roche's new haemophilia drug Hemlibra dramatically reduced bleeding in a broad population of haemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position. Hemlibra cut by 96 percent the incidence of treated bleeds in haemophilia A patients who did not get preventive treatment, and compared with patients who did get preventive treatment in the form of clotting factors it reduced them by 68 percent. The positive results from the two trials known as HAVEN 3 and 4 included so-called non-inhibitor patients.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist6 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks7 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Why Exelixis Stock Fell Last Week
    Market Realist7 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Reuters7 days ago

    Roche immunotherapy combination increases lung cancer survival-study

    Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.

  • The Wall Street Journal7 days ago

    [$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

    The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.

  • Reuters7 days ago

    Roche breast cancer drug treatment time can be halved - study

    Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. Herceptin, a biotech medicine that costs around $76,700 a year in the United States, generated 2017 worldwide sales of more than $7 billion for Roche. If a shorter treatment duration is widely adopted it could significantly reduce sales.

  • Study Finds More Isn't Better for Roche Breast Cancer Drug
    Bloomberg7 days ago

    Study Finds More Isn't Better for Roche Breast Cancer Drug

    For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.

  • Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
    Zacks9 days ago

    Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

    FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

  • Merck Focuses on Multiple R&D Programs for Keytruda in 2018
    Market Realist13 days ago

    Merck Focuses on Multiple R&D Programs for Keytruda in 2018

    On April 15, Merck (MRK) in collaboration with the European Organisation for Research and Treatment of Cancer (or EORTC) announced positive results from the Phase 3 KEYNOTE-054 trial, which highlighted the efficacy of Keytruda as adjuvant therapy for high-risk stage III melanoma patients who have previously undergone surgery.

  • Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
    Zacks13 days ago

    Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

    Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

  • Label Expansion May Boost Keytruda’s Revenue Prospects in 2018
    Market Realist13 days ago

    Label Expansion May Boost Keytruda’s Revenue Prospects in 2018

    Merck’s (MRK) Keytruda has managed to secure U.S. Food and Drug Administration (or FDA) approval in ten different indications across seven tumor types: melanoma, urothelial cancer, classical Hodgkin lymphoma, squamous cell carcinoma of head and neck, non-small cell lung cancer (or NSCLC), gastric cancer, and solid tumors that have microsatellite instability (or MSI) or DNA mismatch repair deficiency. The drug has already emerged as the leading immunotherapy in metastatic NSCLC, bladder cancer, and head and neck cancer indications.

  • Keytruda Continues to Be Major Growth Driver for Merck in 2018
    Market Realist13 days ago

    Keytruda Continues to Be Major Growth Driver for Merck in 2018

    In 1Q18, Merck’s (MRK) Keytruda reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of around 151%. The rise was attributable to the highest number of new patient starts for Keytruda in the US as compared to other immunotherapy drugs such as Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tecentriq. The drug has established itself as a leading therapy for metastatic lung cancer in the US.